Regulation - Halaven

Filter

Current filters:

Halaven

Popular Filters

Eisai's Halaven now available in Russia for advanced breast cancer

Eisai's Halaven now available in Russia for advanced breast cancer

18-12-2014

Halaven (eribulin) manufactured by Japanese drug major Eisai is now available in Russia.

EisaiHalavenOncologyPharmaceuticalRegulationRussia

IQWIG confirms an additional benefit of Eisai's Halaven

IQWIG confirms an additional benefit of Eisai's Halaven

04-11-2014

Following a benefit:cost re-assessment, the German Institute for Quality and Efficiency in Health Care…

EisaiGermanyHalavenOncologyPharmaceuticalPricingRegulation

Eisai’s breast cancer drug Halaven receives MAA in Europe

Eisai’s breast cancer drug Halaven receives MAA in Europe

03-07-2014

The European Commission has issued Marketing Authorization Approval (MAA) for Halaven (eribulin) from…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

Eisai files for new Halaven indication; gets orphan status for lenvatinib in EU

08-05-2013

Japanese drug major Eisai (TYO: 4523) has filed a Type II Variation application with the European Medicines…

EisaiEuropeHalavenlenvatinibOncologyPharmaceuticalRegulation

Eisai expands in South Africa, filing for approval of Halaven and Fycompa

30-01-2013

Japanese drug major Eisai (TYO: 4523) says it is expanding its operations into South Africa, with the…

EisaiFycompaHalavenMarkets & MarketingNeurologicalOncologyPharmaceuticalRegulationRest of the World

Eisai gets South Korean approval for breast cancer drug Halaven

04-09-2012

The South Korean sales subsidiary of Japanese drug major Eisai (TYO: 4523) has received approval from…

Asia-PacificEisaiHalavenOncologyPharmaceuticalRegulation

Zonegran Russian approval prompts Eisai's expansion in that market

28-06-2012

Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

Eisai breast cancer drug still viewed as not cost effective by NICE

03-04-2012

In a third rejection, the UK drug watchdog the National Institute for Health and clinical Excellence…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top